Osteopontin is linked with AKT, FoxO1, and myostatin in skeletal muscle cells.
- Additional Document Info
- View All
INTRODUCTION: Osteopontin (OPN) polymorphisms are associated with muscle size and modify disease progression in Duchenne muscular dystrophy (DMD). We hypothesized that OPN may share a molecular network with myostatin (MSTN). METHODS: Studies were conducted in the golden retriever (GRMD) and mdx mouse models of DMD. Follow-up in-vitro studies were employed in myogenic cells and the mdx mouse treated with recombinant mouse (rm) or human (Hu) OPN protein. RESULTS: OPN was increased and MSTN was decreased and levels correlated inversely in GRMD hypertrophied muscle. RM-OPN treatment led to induced AKT1 and FoxO1 phosphorylation, microRNA-486 modulation, and decreased MSTN. An AKT1 inhibitor blocked these effects, whereas an RGD-mutant OPN protein and an RGDS blocking peptide showed similar effects to the AKT inhibitor. RMOPN induced myotube hypertrophy and minimal Feret diameter in mdx muscle. DISCUSSION: OPN may interact with AKT1/MSTN/FoxO1 to modify normal and dystrophic muscle. Muscle Nerve 56: 1119-1127, 2017.
author list (cited authors)
Nghiem, P. P., Kornegay, J. N., Uaesoontrachoon, K., Bello, L., Yin, Y., Kesari, A., ... Hoffman, E. P.
complete list of authors
Nghiem, Peter P||Kornegay, Joe N||Uaesoontrachoon, Kitipong||Bello, Luca||Yin, Ying||Kesari, Akanchha||Mittal, Priya||Schatzberg, Scott J||Many, Gina M||Lee, Norman H||Hoffman, Eric P